• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
CHEN Siyi, LAI Maode. Expression changes of S100 family proteins and their functional significances in renal cancer[J]. Journal of China Pharmaceutical University, 2020, 51(2): 223-230. DOI: 10.11665/j.issn.1000-5048.20200214
Citation: CHEN Siyi, LAI Maode. Expression changes of S100 family proteins and their functional significances in renal cancer[J]. Journal of China Pharmaceutical University, 2020, 51(2): 223-230. DOI: 10.11665/j.issn.1000-5048.20200214
shu

Expression changes of S100 family proteins and their functional significances in renal cancer

More Information
    Graphical Abstract
    • Abstract
  • Renal cell carcinoma is a common type malignant tumor of the urinary system. The global incidence of renal cancer is 2. 2%. S100 proteins are involved in the regulations of proliferation, differentiation, apoptosis, and Ca2+ homeostasis, etc. S100 proteins are often closely associated with tumor progression. This review lists the expression changes of S100s and their functional significances in renal cancers, providing a new direction for the researches and treatments of renal cancer. The interpretation of S100 in the regulation of VHL/HIF signaling pathways should be a future direction.
    • FullText(HTML)
    • References (37)
  • [1]
    Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
    [2]
    Donato R,Cannon BR,Sorci G,et al.Functions of S100 proteins[J].Curr Mol Med,2013,13(1):24-57.
    [3]
    Teratani T,Watanabe T,Kuwahara F,et al.Induced transcriptional expression of calcium-binding protein S100A1 and S100A10 genes in human renal cell carcinoma[J].Cancer Lett,2002,175(1):71-77.
    [4]
    Liu XH.Expression of S100A1,GLUT-1 and Caveolin-1 in eosinophilic renal cell carcinoma[J].Chin J Pub Health Eng(中国卫生工程学),2017,16(6):754-755.
    [5]
    Rocca PC,Brunelli M,Gobbo S,et al.Diagnostic utility of S100A1 expression in renal cell neoplasms:an immunohistochemical and quantitative RT-PCR study[J].Mod Pathol,2007,20(7):722-728.
    [6]
    Ng KL,Morais C,Bernard A,et al.A systematic review and meta-analysis of immunohistochemical biomarkers that differentiate chromophobe renal cell carcinoma from renal oncocytoma[J].J Clin Pathol,2016,69(8):661-671.
    [7]
    Kuroda N,Kanomata N,Yamaguchi T,et al.Immunohistochemical application of S100A1 in renal oncocytoma,oncocytic papillary renal cell carcinoma,and two variants of chromophobe renal cell carcinoma[J].Med Mol Morphol,2011,44(2):111-115.
    [8]
    Yang JF,Zhang XY,Qi F.Expression of S100 protein in renal cell carcinoma and its relationship with P53[J].J Centrl S Univ(Med Sci)(中南大学学报 医学版),2004,(3):301-304.
    [9]
    Kato K,Haimoto H,Ariyoshi Y,et al.High levels of S-100a0(alpha alpha)protein in tumor tissues and in sera of patients with renal cell carcinoma[J].JAP J Cancer Res Gann,1985,76(9):856.
    [10]
    Zhao CF.Expression and function of S100A2 in renal clear cell carcinoma(S100A2在肾透明细胞癌中的表达及功能研究)[D].Chinese PLA General Hospital & Medical School PLA,2016.
    [11]
    Wang LJ,Matoso A,Sciandra KT,et al.Expression of S100A4 in renal epithelial neoplasms[J].Appl Immunohistochem Mol Morphol,2012,20(1):71-76.
    [12]
    Yang H,Zhao K,Yu Q,et al.Evaluation of plasma and tissue S100A4 protein and mRNA levels as potential markers of metastasis and prognosis in clear cell renal cell carcinoma[J].J Int Med Res,2012,40(2):475-485.
    [13]
    Zhou HK, Zhao YB, Zheng SB, et al. Association of S100A4 expression with differentiation and metastasis of renal cell carcinoma [J].J First Mil Meal Univ(第一军医大学学报),2005,(6):712-714.
    [14]
    Bandiera A,Melloni G,Freschi M,et al.Prognostic factors and analysis of S100a4 protein in resected pulmonary metastases from renal cell carcinoma[J].World J Surg,2009,33(7):1414-1420.
    [15]
    Lin C,Xin ZQ,Wang WP,et al.Expressions of S100A4 protein and E-cadherin in renal cell carcinoma and their clinical significance[J].J Chin Med Univ(中国医科大学学报),2009,38(1):47-49.
    [16]
    Lyu XJ, Li HZ, Ma X, et al. Elevated S100A6(Calcyclin)enhances tumorigenesis and suppresses CXCL14-induced apoptosis in clear cell renal cell carcinoma[J].Oncotarget,2015,6(9):6656-6669.
    [17]
    Lyu X,Li H,Ma X,et al.High-Level S100A6 Promotes metastasis and predicts the outcome of T1-T2 stage in clear cell renal cell carcinoma[J].Cell Biochem Biophys,2015,71(1):279-290.
    [18]
    Korndörfer IP,Brueckner F,Skerra A.The crystal structure of the human(S100A8/S100A9)2 heterotetramer,calprotectin,illustrates how conformational changes of interacting α-helices can determine specific association of two EF-hand proteins[J].J Mol Biol,2007,370(5):887-898.
    [19]
    Zhang L,Jiang H,Xu G,et al.iTRAQ-based quantitative proteomic analysis reveals potential early diagnostic markers of clear-cell Renal cell carcinoma[J].Biosci Trend,2016,10(3):210-219.
    [20]
    Ebbing J,Mathia S,Seibert FS,et al.Urinary calprotectin:a new diagnostic marker in urothelial carcinoma of the bladder[J].World J Urol,2014,32(6):1485-1492.
    [21]
    Hemmerlein B,Markus A,Wehner M,et al.Expression of acute and late-stage inflammatory antigens,c-fms,CSF-1,and human monocytic serine esterase 1,in tumor-associated macrophages of renal cell carcinomas[J].Cancer Immunol Immunother Cii,2000,49(9):485.
    [22]
    Zhang L,Jiang H,Xu G,et al.Proteins S100A8 and S100A9 are potential biomarkers for renal cell carcinoma in the early stages:results from a proteomic study integrated with bioinformatics analysis[J].Mol Med Rep,2015,11(6):4093-4100.
    [23]
    Mirza Z,Schulten HJ,Farsi HM,et al.Molecular interaction of a kinase inhibitor midostaurin with anticancer drug targets,S100A8 and EGFR:transcriptional profiling and molecular docking study for kidney cancer therapeutics[J].PLoS One,2015,10(3):e119765.
    [24]
    Mirza Z,Schulten H,Farsi HM,et al.Impact of S100A8 expression on kidney cancer progression and molecular docking studies for kidney cancer therapeutics[J].Anticancer Res,2014,34(4):1873.
    [25]
    Kwon M,MacLeod TJ,Zhang Y,et al.S100A10,annexin A2,and annexin A2 heterotetramer as candidate plasminogen receptors[J].Front Biosci,2005,10:300-325.
    [26]
    Domoto T,Miyama Y,Suzuki H,et al.Evaluation of S100A10,annexin II and B-FABP expression as markers for renal cell carcinoma[J].Cancer Sci,2007,98(1):77-82.
    [27]
    Na CH,Hong JH,Kim WS,et al.Identification of protein markers specific for papillary renal cell carcinoma using imaging mass spectrometry[J].Mol Cells,2015,38(7):624-629.
    [28]
    Gabril M,Girgis H,Scorilas A,et al.S100A11 is a potential prognostic marker for clear cell renal cell carcinoma[J].Clin Eep Metastas,2016,33(1):63-71.
    [29]
    Liu L,Miao L,Liu Y,et al.S100A11 regulates renal carcinoma cell proliferation,invasion,and migration via the EGFR/Akt signaling pathway and E-cadherin?偊潝眮氼敩猾?呵??瑲欠楂湩獯????椾??攰琱?愬氼???椹??瑢放稨漵氩椺稵甶洸愸戳‵瀱氶申献?扢敲瘾慛挳椰穝甠洠慅扲?癮攠牎猬異獥?猦産湸楅琷椻湩椠扔?楁湫?灡慹瑡椠敂渼瑩猾?睥楴琠桡?瀮爼支癩椾潎略獵汲祯?略湰瑴物敤慥琠敌摥?浥敬瑳愠獡瑳愠瑷楥捬?爠敡湳愠汮?捰敲汩汬?捳慩牮挠楡湣潴浩慶???洠潤瑥楣潲湥?????慮?浲略汮瑡楬挠散湥瑬牬攠?潡灲散湩?汯慭扡敛汊?瀮格慩猾敃???牥慲渠摍潩浣楲獯敥摮?捩潲湯瑮牭潥汮汴攼搯?琾爬椲愰氱嬶?崼??椹??慢渾挨攲琯??椺??祝?????扛??????扣???????????お????????扄牊?孂??崠??吼敩猾愬牥潴瘠慡?倮??慩氾潓畯獭潡癴慩???婸楰浲慥?味?楯??敯瑦?慅汎???楅???????卯?どち?灥牤漠瑷敩楴湨猠?慢湥摳?潴瑹栠敳牴?剴????汭楯杮慧渠摰獡?楩湥?捴慳渠捷敩牴???浬慥牡歲攠牣獥?浬攠摲楥慮瑡潬爠獣?慬湬搠?灡畲瑣慩瑮楯癭敡?瑊桝攮爼慩瀾敃畡瑲楣捩?瑯慧牥杮敥瑳獩孳?崼??椾??椰漱洴攬搼?倾愳瀵??敢搾??愩挺?唲渲椭瘸′倷愮氼慢捲款祛″伲汝漠洠潎畡捺??穩攠捁栬?剨敯灲畲扡??楥???ち????扈???ち??扨???????????戠牡?嬮??嵩￣?娱栰愰湁朱′??婮栠慲湥杮?公?噡???慣湡摲?桩祯灶潡硳楣慵?獡楲朠湤慩汳楥湡杳?扳敛祊潝渮搼?????楥渠?捣慩渼振敩爾嬬?崰??椬??椾漱洹攱搼椯换椾渺攲猵??椲??金?????戳????托????????S,Liu Y,et al.Expression and significance of S100P in human renal clear cell carcinoma[J].J Clin Urol(临床泌尿外科杂志),2014,29(9):776-779.
    [30]
    Truong LD, Shen SS. Immunohistochemical diagnosis of renal neoplasms[J].Arch Pathol Lab Med,2011,135(1):92-109.
    [31]
    Teratani T,Watanabe T,Yamahara K,et al.Restricted expression of calcium-binding protein S100A5 in human kidney[J].Biochem Biophys Res Commun,291(3):627.
    [32]
    Molina AM,Hutson TE,Nosov D,et al.Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma:crossover of a phase 3 study[J].Eur J Cancer,2018,94:87-94.
    [33]
    Motzer RJ,Escudier B,McDermott DF,et al.Nivolumab versus everolimus in advanced renal-cell carcinoma[J].N Engl J Med,2015,373(19):1803-1813.
    [34]
    Motzer RJ,Tannir NM,McDermott DF,et al.Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma[J].N Engl J Med,2018,378(14):1277-1290.
    [35]
    Rini BI,Plimack ER,Stus V,et al.Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma[J].N Engl J Med,2019,380(12):1116-1127.
    [36]
    Motzer RJ,Penkov K,Haanen J,et al.Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma[J].N Engl J Med,2019,380(12):1103-1115.
    [37]
    Rini BI
    • Related Articles

  • Related Articles

    [1]CAI Xu, WU Xiaoqian, HAN Lingfei, FENG Feng, QU Wei, LIU Wenyuan. Research progress on natural products regulating osteogenic differentiation[J]. Journal of China Pharmaceutical University, 2025, 56(1): 10-21. DOI: 10.11665/j.issn.1000-5048.2024101003
    [2]ZHANG Qili, TIAN Xue, WANG Jie, ZHAO Lei, XIA Pengfei, XU Yanli, XU Fumei, JIA Yinqiang. Research progress of nitroxide radical derivatives and their biological activities[J]. Journal of China Pharmaceutical University, 2024, 55(5): 673-684. DOI: 10.11665/j.issn.1000-5048.2023041902
    [3]YAO Chunlu, ZHANG Weijie, ZHANG Yunlong, DENG Zhaoxia, WANG Mengling, ZHANG Zuoling, WANG Chen, SONG Qinxin, ZOU Bingjie. Progress of single-cell protein imaging methods[J]. Journal of China Pharmaceutical University, 2024, 55(2): 147-157. DOI: 10.11665/j.issn.1000-5048.2024010205
    [4]LU Zhipeng, XU Qinglong, CHEN Panpan, QIN Yajuan, TANG Lijun, LI Tingyou. Research progress of radioprobes targeting fibroblast activating protein[J]. Journal of China Pharmaceutical University, 2022, 53(6): 651-662. DOI: 10.11665/j.issn.1000-5048.20220603
    [5]YANG Wanwan, YE Fangyu, WU Yujia, WANG Haochen, ZHAO Li. Research progress of PARP inhibitors in cancers and their drug resistance[J]. Journal of China Pharmaceutical University, 2022, 53(5): 525-534. DOI: 10.11665/j.issn.1000-5048.20220503
    [6]WANG Zhenghao, GAO Yafeng, ZHANG Lianjun, LIU Chang. Research progress of T cell anti-tumor function regulated by endoplasmic reticulum stress[J]. Journal of China Pharmaceutical University, 2022, 53(5): 518-524. DOI: 10.11665/j.issn.1000-5048.20220502
    [7]WANG Chen, XU Jun, LIU Yanhua, WANG Zengtao, HU Yue, TIAN Taiping, YI Mengjuan. Research progress on functionalized graphene oxide as drug carriers[J]. Journal of China Pharmaceutical University, 2017, 48(1): 117-124. DOI: 10.11665/j.issn.1000-5048.20170118
    [8]ZHANG Danfeng, JIAO Yu, LIU Yong, ZHANG Yanmin, ZHANG Zhimin, LU Tao. Progress of small molecule anti-tumor covalent drugs[J]. Journal of China Pharmaceutical University, 2017, 48(1): 1-7. DOI: 10.11665/j.issn.1000-5048.20170101
    [9]HU Yue, CHEN Zhou, LUO Xiaoxing, XUE Xiaoyan. Research progress of 1, 2-dilinoleyloxy-3-dimethylaminopropane-based cationic lipid nanoparticle[J]. Journal of China Pharmaceutical University, 2016, 47(1): 112-117. DOI: 10.11665/j.issn.1000-5048.20160117
    [10]ZHANG Jinghui, WANG Yajing, HU Rong. Roles of Moesin in tumor progression[J]. Journal of China Pharmaceutical University, 2015, 46(3): 371-375. DOI: 10.11665/j.issn.1000-5048.20150319

  • Cited by

    Periodical cited type(6)

    1. 金伟斌，陈礼峰，唐倩倩，顾晓风. 顶空气相色谱法测定生脉注射液中甲醛和乙醛的含量. 中国合理用药探索. 2022(06): 115-120 .
    2. 李浩宇，唐宝强，何东升，涂家生. 气相色谱法测定药用辅料聚西托醇1000中的残留杂质. 中国药科大学学报. 2022(03): 293-299 . 本站查看
    3. 王贺，钱利武，阚红卫. 药用辅料监管法规、质量标准现状分析及应对措施. 中南药学. 2022(08): 1937-1941 .
    4. 庞丽然，贺丞，杜力，刘国芳. 重组蛋白中吐温80含量硫氰酸铵钴显色检测法的改进及验证. 中国生物制品学杂志. 2021(09): 1111-1113+1119 .
    5. 郑永强，付俊伟，朱慧敏，陶晓军. 一种用于实现脑靶向的负载长春新碱抗肿瘤纳米药物制剂的制备及表征. 肿瘤药学. 2021(05): 547-553 .
    6. 黄婧，吴宏伟. 依诺沙星滴眼液辅料及药包材相容性研究. 中国现代应用药学. 2021(22): 2802-2806 .

    Other cited types(2)

Catalog

    Get Citation
    PDF
    XML
    Article views (485) PDF downloads (1129) Cited by(8)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：304011

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return